Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

First-of-Its-Kind Diabetic Retinopathy Treatment Approved Roche’s Susvimo is now the first and only FDA-approved continuous ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) today announced that it obtained regulatory approval from the Ministry ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Steven T. Reed, O.D., discusses age-related macular degeneration (AMD), the leading cause of severe vision loss in adults ...